Answer to Question 1
Correct Answer: 3,4,5
Rationale 1: Telemarketing of pills that produce easy weight loss is usually too good to be true.
Rationale 2: Until 2004, alternative weight loss products contained ephedra alkaloids, but these have also been removed from the market due to an increased incidence of adverse cardiovascular events.
Rationale 3: The substance fenfluramine is suspected of causing heart valvular disease.
Rationale 4: Trials of leptin as a weight-reduction strategy have not proven to be effective.
Rationale 5: Dexedrine, a highly addictive stimulant, is no longer prescribed for weight reduction.
Global Rationale: The substance fenfluramine is suspected of causing heart valvular disease. Trials of leptin as a weight-reduction strategy have not proven to be effective. Dexedrine, a highly addictive stimulant, is no longer prescribed for weight reduction. Telemarketing of pills that produce easy weight loss is usually too good to be true. Until 2004, alternative weight loss products contained ephedra alkaloids, but these have also been removed from the market due to an increased incidence of adverse cardiovascular events.
Answer to Question 2
Correct Answer: 3
Rationale 1: Sibutramine (Meridia) does not cause postnasal drainage, pruritus, and drowsiness.
Rationale 2: Headache, constipation, and xerostomia are common adverse effects of sibutramine (Meridia) but they did not cause the medication to be removed from the market.
Rationale 3: Sibutramine (Meridia) was removed from the market in 2010 due to the increased risk of heart attack and stroke that were associated with the medication.
Rationale 4: Facial twitching, backache, and anxiety are not associated with sibutramine (Meridia).
Global Rationale: From 2007 until 2010, sibutramine (Meridia) was approved for the adjunctive treatment of obesity. The drug was able to produce a 5 to 10 loss of body weight within 6 to 12 months of treatment. Although well tolerated by most patients, sibutramine was found to produce an unacceptable incidence of serious cardiac events and stroke and was voluntarily removed from the market. It did not produce the other effects.